Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder (MAP-S-01)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Sheba Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT01320982
First received: February 2, 2011
Last updated: March 22, 2011
Last verified: March 2011

February 2, 2011
March 22, 2011
March 2011
June 2012   (final data collection date for primary outcome measure)
  • Positive and Negative Syndrome Scale (PANSS)total score [ Time Frame: Positive and Negative Syndrome Scale (PANSS) total score at week 8 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS)total score at 8 weeks
  • Positive and Negative Syndrome Scale (PANSS)total score [ Time Frame: Positive and Negative Syndrome Scale (PANSS) total score at week 16 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS)total score at 16 weeks.
Same as current
Complete list of historical versions of study NCT01320982 on ClinicalTrials.gov Archive Site
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS)positive sub-scale score at week 2 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale scoreat 2 weeks.
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale(PANSS) positive sub-scale score at week 4 . ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale(PANSS) positive sub-scale score at 4 weeks.
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and negative syndrome scale(PANSS) positive sub-scale score at week 8. ] [ Designated as safety issue: No ]
    Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale score at 8 weeks.
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and negative syndrome scale(PANSS) positive sub-scale score at week 16. ] [ Designated as safety issue: No ]
    Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale score at 16 weeks.
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 2 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 2 weeks
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 4 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 4 weeks
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 8 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 8 weeks
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 16 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 16 weeks
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 2 weeks ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 2
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 4 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 4 weeks
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 8 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 8 weeks
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at week 16 ] [ Designated as safety issue: No ]
    Change from baseline in Positive and Negative Syndrome Scale (PANSS) general psychopathology sub-scale score at 16 weeks
  • Clinical Global Impression Scale-Severity (CGI-S) [ Time Frame: Clinical Global Impression Scale-Improvement (CGI-S) at week 2 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 2 weeks
  • Clinical Global Impression Scale-Severity (CGI-S) [ Time Frame: Clinical Global Impression Scale-Severity (CGI-S) at week 5 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 5 weeks
  • Clinical Global Impression Scale-Severity(CGI-S) [ Time Frame: linical Global Impression Scale-Severity(CGI-S) at week 8 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 8 weeks
  • Clinical Global Impression Scale-Severity(CGI-S) [ Time Frame: Change from baseline in Clinical Global Impression Scale-Severity(CGI-S) at week 12 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 12 weeks
  • Clinical Global Impression Scale-Severity(CGI-S) [ Time Frame: Change from baseline in Clinical Global Impression Scale-Severity(CGI-S) at week 16 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale-Severity(CGI-S)at 16 weeks
  • Clinical Global Impression Scale- Improvement (CGI-I) [ Time Frame: Clinical Global Impression Scale- Improvement (CGI-I) at week 2 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 2 weeks
  • Clinical Global Impression Scale- Improvement (CGI-I) [ Time Frame: Clinical Global Impression Scale- Improvement (CGI-I) at week 5 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 5 weeks
  • Clinical Global Impression Scale- Improvement (CGI-I) [ Time Frame: Clinical Global Impression Scale- Improvement (CGI-I)at week 8 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 8 weeks
  • Clinical Global Impression Scale- Improvement (CGI-I) [ Time Frame: Clinical Global Impression Scale- Improvement (CGI-I) at week 12 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 12 weeks
  • Clinical Global Impression Scale- Improvement (CGI-I) [ Time Frame: Clinical Global Impression Scale- Improvement (CGI-I)at week 16 ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression Scale- Improvement (CGI-I)at 16 weeks
  • Brief Assessment of Cognition in Schizophrenia (BACS) [ Time Frame: rief Assessment of Cognition in Schizophrenia (BACS)at week 8 ] [ Designated as safety issue: No ]
    Change from baseline in Brief Assessment of Cognition in Schizophrenia (BACS)at 8 weeks.
  • Brief Assessment of Cognition in Schizophrenia (BACS) [ Time Frame: Brief Assessment of Cognition in Schizophrenia (BACS)at week 16 ] [ Designated as safety issue: No ]
    Change from baseline in Brief Assessment of Cognition in Schizophrenia (BACS)at 16 weeks.
Same as current
Not Provided
Not Provided
 
Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder

The objective of the study is to evaluate the efficacy of Pramipexole, Minocycline and Aspirin compared to placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia.

Inflammatory processes have been implicated as a cause of schizophrenia (Fan, Goff et al. 2007), and the COX-2 inhibitor, Celecoxib, has been shown to reduce symptoms of schizophrenia (Muller, Krause et al. 2010). Aspirin, which is also a non-steroidal anti-inflammatory drug(NSAID), irreversibly inhibits Cyclooxygenase-1 (COX-1) and modifies the enzymatic activity of Cyclooxygenase-2 (COX-2), thus inhibiting the formation of prostaglandins and reduces inflammatory reaction. In a study funded by the Stanley Medical Research Institute (SMRI) recently published, Laan at all (Laan, Grobbee et al. 2010) administered add-on 1000mg/d of Aspirin to patients with schizophrenia receiving anti-psychotics, and reported reductions in Positive and negative syndrome scale (PANSS) total and PANSS positive scores without substantial side effects.

Minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile. Minocycline effects the glutaminergic system, through inhibition of neuronal nitric oxide synthase (nNOS) and blocking of nitric oxide (NO)- induced neurotoxicity (Du et al, 1998; Jiang et al., 2005), and thus has been suggested as a potential treatment for schizophrenia. One published study (Levkovitz, Mendlovich et al. 2010), and another, unpublished study by Bill Deakin found that add-on treatment of 200mg/d of Minocycline was beneficial for symptoms and cognition in schizophrenia, and a study by Miayoka et al (Miyaoka, Yasukawa et al. 2008) administered open-label 450 mg/day Minocycline, and found improvement on positive symptoms.

Indirect pharmacological evidence suggests a relative excess of dopaminergic activity as being implicated in the pathogenesis of some of the symptoms of schizophrenia, and all effective antipsychotics effect dopamine D2 receptors. Pramipexole is a pre-synaptic dopamine auto-receptor agonist hypothesized to improve in symptoms in schizophrenia patients. In an open label study, Kasper at all (Kasper, Barnas et al. 1997) showed statistically significant improvement in PANSS scores in patients not stabilized on haloperidol. Other data indicate that add-on Pramipexole improves symptoms of depression and cognition, in patients with affective disorders (Goldberg, Frye et al. 1999; Sporn, Ghaemi et al. 2000; Goldberg, Burdick et al. 2004; Zarate, Payne et al. 2004), and Malhotra et al, unpublished data.

All of these studies were relatively small, and were performed by investigators with an interest in the compound. The objective of this study is to replicate them in large trial by investigators with no specific interest in the compounds. This proposed study is a multi-arm study, in which patients will be randomized to one of the three study drugs: Pramipexole, Minocycline and Aspirin, or placebo as part of the same protocol. A design by which several active compounds are all compared to the same placebo arm has been utilized before for schizophrenia (Meltzer, Arvanitis et al. 2004). This design has several advantages: in addition to reduced costs and time it exposes fewer patients to placebo, and enables direct comparison between the compounds and not only to the placebo.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Schizophrenia
  • Schizoaffective Disorder
  • Drug: minocycline
    minocycline 100 mg/bid
  • Drug: pramipexole
    pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
  • Drug: acetylsalicylic acid
    acetylsalicylic acid 500mg/ bid
  • Drug: placebo
    placebo bid
  • Active Comparator: minocycline
    minocycline
    Intervention: Drug: minocycline
  • Active Comparator: pramipexole
    pramipexole
    Intervention: Drug: pramipexole
  • Active Comparator: acetylsalicylic acid
    acetylsalicylic acid
    Intervention: Drug: acetylsalicylic acid
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
400
July 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female, 18-65 years of age, inclusive
  2. Females who are abstinent or practicing an established method of birth control (oral contraceptive tablets, hormonal implant device, hormone patch, injectable contraceptive, intrauterine device.
  3. Willing and able to provide informed consent, after the nature of the study has been fully explained
  4. Current DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder as confirmed by modified Structured Clinical Interview for DSM Disorders (SCID) and having had at least 2 prior schizophrenic episodes, or continually ill for at least 6 months.
  5. Symptoms: 4 (moderate) or above on Clinical Global Impression scale (CGI-S)and 4 (moderate)or above score on two of the following four Positive and negative syndrome scale (PANSS) items: delusions, hallucinatory behaviors, conceptual disorganization or suspiciousness/ persecution, and/or a total PANSS negative symptoms score of 18.
  6. Must be on any antipsychotic drug, for at least 2 weeks prior to the baseline visit, at doses within the Patient Outcome Research Team (PORT) criteria, whenever possible. Patients receiving higher doses will have their records reviewed to insure that their dose is required and, if possible, will be stabilized on a lower dose prior to study entry.
  7. Inpatients or outpatients. Inpatients will be randomized 3 days or more after admission

Exclusion Criteria:

  1. Unwilling or unable, in the opinion of the Investigator, to comply with study instructions
  2. Pregnant or breast-feeding
  3. Unstable medical disease (malignancy, poorly controlled diabetes, active ischemic cardiac disease, or cardiomyopathy, serious pulmonary disease, kidney disease, impaired liver functioning. History of hemorrhagic CVA or peptic ulcer disease.
  4. Patients treated with: any of the trial medications i.e. pramipexole/minocycline/ acetylsalicylic acid, NSAIDs, anti-coagulants, sucralfate, cimetidine, amantadine, mexiletine.
  5. Likely allergy or sensitivity to raloxifene/pramipexole/minocycline/acetylsalicylic acid.
  6. At significant risk of committing suicide, or in the opinion of the Investigator, currently is at imminent risk of suicide or harming others.
  7. Patients with a current DSM-IV substance or alcohol abuse. Patients with a history of and/or current recreational use of cannabinoids or alcohol, and/or patients who smoke cigarettes can be included.
  8. Concurrent delirium, mental retardation, drug-induced psychosis, or history of clinically significant brain trauma documented by CT or MRI.
Both
18 Years to 65 Years
No
Contact: Mark Weiser, MD 972-52-6666575 mweiser@netvision.net.il
Contact: Katya Rubinstein, MA 972-3-5303454 rubins.katya@gmail.com
Israel,   Romania
 
NCT01320982
SHEBA-8273-10-MW-CTIL
No
Mark Weiser MD (PI), Sheba Medical Center
Sheba Medical Center
Not Provided
Principal Investigator: Mark Weiser, MD Sheba Medical Center
Sheba Medical Center
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP